Insider Buying: Lantern Pharma (NASDAQ:LTRN) Director Buys $100,000.64 in Stock

Posted by Brenda Bartman on May 17th, 2026

Lantern Pharma Inc. (NASDAQ:LTRN – Get Free Report) Director D Jeffrey Keyser bought 48,544 shares of the stock in a transaction dated Tuesday, May 12th. The shares were purchased at an average price of $2.06 per share, for a total transaction of $100,000.64. Following the purchase, the director owned 94,303 shares of the company’s stock, valued at $194,264.18. This trade represents a 106.09% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Lantern Pharma Trading Up 0.3%

Shares of NASDAQ LTRN opened at $3.14 on Friday. The firm has a market cap of $35.51 million, a P/E ratio of -2.17 and a beta of 2.10. Lantern Pharma Inc. has a 1-year low of $1.11 and a 1-year high of $5.74. The business’s 50 day moving average is $2.22 and its 200-day moving average is $2.92.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LTRN. Weiss Ratings upgraded Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded Lantern Pharma to a “sell” rating in a research note on Saturday, May 9th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lantern Pharma currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Lantern Pharma

Hedge Funds Weigh In On Lantern Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Lantern Pharma by 5.6% during the 3rd quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after acquiring an additional 20,321 shares during the period. CM Management LLC boosted its holdings in shares of Lantern Pharma by 12.5% in the 3rd quarter. CM Management LLC now owns 225,000 shares of the company’s stock valued at $979,000 after purchasing an additional 25,000 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Lantern Pharma by 5.1% in the 1st quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock valued at $159,000 after purchasing an additional 5,600 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Lantern Pharma by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after purchasing an additional 4,661 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in shares of Lantern Pharma in the 3rd quarter valued at $170,000. Institutional investors own 28.62% of the company’s stock.

About Lantern Pharma

(Get Free Report)

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.